Cathie Wood’s Ark Invest cut exposure to crypto-linked stocks and boosted positions in traditional technology and biotechnology on April 18, in a move that signals a tactical shift toward companies with clearer earnings visibility and regulatory footing.
Key moves on April 18
- Sold about $2.57 million of crypto-related stocks
- Bought roughly $14.5 million of traditional tech and biotech names
Crypto-related sales
Ark trimmed holdings in two digital asset infrastructure names:
- Circle Internet Group
Sold: 11,465 shares
Value: roughly $1.21 million - Bullish
Sold: 31,417 shares
Value: around $1.36 million
Circle has come under pressure from a class-action lawsuit linked to a security incident at Drift Protocol, which uses its technology. The case has raised fresh questions about legal and operational risks for stablecoin issuers.
Bullish, which reported March 2026 trading volume of $60.4 billion, has benefited from improving sentiment in digital assets. Its shares rose about 5% on the day and are up 13.40% month over month, during a period when the broader market’s sentiment score sits in “Greed” territory at 61 out of 100. Locking in some of these gains points to a disciplined profit-taking strategy despite the upbeat backdrop.
Rotation into Netflix and Alamar Biosciences
At the same time, Ark increased exposure to more conventional growth stories in media and healthcare.
Netflix purchase after earnings drop
- Netflix
Bought: 26,161 shares
Value: about $2.54 million
Netflix posted first-quarter revenue of $12.25 billion and profit of $5.28 billion, slightly ahead of forecasts. Yet the stock fell nearly 10% after the report, pressured by cautious forward guidance and the exit of co-founder Reed Hastings from the board.
Buying into that weakness suggests a classic move to add to a strong underlying business after a pullback. Netflix’s advertising unit is on track to double revenue to around $3 billion this year, reinforcing the view that its core operations remain solid despite short-term sentiment swings.
Big bet on newly listed Alamar Biosciences
- Alamar Biosciences
Bought: 537,463 shares
Value: roughly $11.96 million
Alamar, which specializes in protein biomarker detection technology, listed on Nasdaq this week. The stock surged about 33% on its first trading day, lifting the company’s market value to about $1.53 billion.
Ark’s large allocation into Alamar during its debut week marks a decisive tilt toward high-growth healthcare. The company operates in proteomics, a field that posted revenue growth of more than 195% year over year in 2025, underscoring strong demand for advanced biomarker and diagnostic tools.
Strategic implications
Taken together, the trades point to a measured de-risking away from digital asset platforms facing legal and operational uncertainty, and toward businesses with:
- Strong or accelerating revenue profiles
- More established or conventional regulatory frameworks
- Clear, fundamental growth narratives in media and biotechnology
Reducing positions in Circle and Bullish while rotating into Netflix and Alamar reflects a preference, at this stage, for companies anchored by tangible cash flows or scientific innovation over those more exposed to the still-maturing crypto ecosystem.
Shifting from volatile crypto to regulated assets? Learn how digital currencies work in our guide to cryptocurrency fundamentals today.
Disclaimer: The content on this page is provided for general informational purposes only and does not represent the views or financial advice of Toobit. We make no guarantees regarding the accuracy or completeness of this information and shall not be held liable for any errors, omissions, or outcomes resulting from its use. Investing in digital assets involves risk; users should independently evaluate their financial situation and the risks involved. For further details, please consult our Terms of Service and Risk Disclosure.
